Lapsed Oct 9, 2026 on the fee record · High confidence
20-year base term ends Oct 15, 2033
Second maintenance fee unpaid; grace period ended.
Held by Epizyme, Inc.
Filed Apr 14, 2015 as application 14/435,704 · Granted Oct 9, 2018
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
Lapsed Oct 9, 2026
2013
2033
Clock starts
Oct 15, 2013
Oct 15, 2013
No longer in force
Oct 9, 2026
Oct 9, 2026
Granted
Oct 9, 2018
Oct 9, 2018
Term would have run to
Apr 13, 2032
Apr 13, 2032
base term
after the term ends
fee events
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,410,088, US 9,090,562.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
Its term would have run to Apr 13, 2032: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 15, 2013, when application PCT/US2013/065127, the earliest non-provisional in its chain, was filed (this one was filed Apr 14, 2015) | Oct 15, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,410,088, US 9,090,562) | capped to Apr 13, 2032 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | lapsed Oct 9, 2026 | High confidence |
| Computed term end | The steps above, in order | Oct 9, 2026 | High confidence |
This family
| Application PCT/US2013/065127 | PCT application no patent term | no patent term |
| US 10,092,572 | this patent Oct 2026 | Oct 2026 |
| Application 16/120,702 | Abandoned not computed | not computed |
| US 11,642,348 | In force Apr 2032 | Apr 2032 |
| Application 18/188,700 | Abandoned not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 15, 2015 Reel 35411, frame 624 | Kuntz, Kevin Wayne; Campbell, John Emmerson | Epizyme, Inc. | Assignment of Assignor's Interest |
| Apr 15, 2015 Reel 35411, frame 645 | Seki, Masashi; Shirotori, Syuji; Intano, Wataru; Zheng, Wanjun | Eisai R&D Management Co., Ltd. | Assignment of Assignor's Interest |
| Apr 17, 2015 Reel 35435, frame 697 | Eisai R&D Management Co., Ltd. | Epizyme, Inc. | Assignment of Assignor's Interest |
| Nov 19, 2019 Reel 51057, frame 848 | Epizyme, Inc. | Biopharma Credit PLC | Security Interest |
| Aug 13, 2022 Reel 61165, frame 501 | Biopharma Credit PLC | Epizyme, Inc. | Termination and Release of Security Interest in Patents at Reel/Frame: 051057/0848 |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,410,088, US 9,090,562.
Citations
16
later US patents cite this one
That is top 25% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.